Literature DB >> 6798926

Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa.

P R Michael, R H Alford, Z A McGee.   

Abstract

N-Formimidoyl thienamycin (N-F-thienamycin), cefotaxime, moxalactam, and cefsulodin were tested by agar dilution against 125 isolates of Pseudomonas aeruginosa, Serratia marcescens, Klebsiella pneumoniae, and Providencia stuartii. Against gentamicin-susceptible P. aeruginosa, N-F-thienamycin and cefsulodin were most active. Only N-F-thienamycin inhibited gentamicin-resistant P. aeruginosa at less than or equal to 4 microgram/ml. N-F-thienamycin's activity equaled or surpassed that of the other antibiotics tested against both the gentamicin-susceptible and -resistant Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6798926      PMCID: PMC181780          DOI: 10.1128/AAC.20.5.702

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.

Authors:  R Wise; T Rollason; M Logan; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

2.  Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.

Authors:  W H Hall; B J Opfer; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

4.  In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli.

Authors:  D G Delgado; C J Brau; C G Cobbs; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

5.  In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

6.  Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations.

Authors:  L S Young; W J Martin; R D Meyer; R J Weinstein; E T Anderson
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

7.  LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas.

Authors:  D J Flournoy; F A Perryman
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

8.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

10.  In vitro antibacterial activity and susceptibility of cefsulodin, an antipseudomonal cephalosporin, to beta-lactamases.

Authors:  A King; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

View more
  6 in total

1.  Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; J Klastersky; H Lagast; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  In vitro activity of carumonam (RO 17-2301) and twelve other antimicrobials against clinical isolates of Pseudomonas aeruginosa.

Authors:  U Vurma-Rapp; F H Kayser
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

3.  Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I).

Authors:  Sung Wook Park; Jeoung Soon We; Gye Won Kim; Seong Hak Choi; Haeng Soon Park
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Epidemiology of gentamicin-resistant, gram-negative bacillary colonization in a spinal cord injury unit.

Authors:  D M Shlaes; C A Currie; G Rotter; M Eanes; R Floyd
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.

Authors:  C R Magnussen; M T Sammartino; K D Ernest
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.